Paper
Structure-activity relationships of 2,4-diphenyl-1H-imidazole analogs as CB2 receptor agonists for the treatment of chronic pain.
Published 2011 · Shu-wei Yang, Jennifer Smotryski, J. Matasi
Bioorganic & medicinal chemistry letters
Q2 SJR score
11
Citations
0
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
Study Snapshot
2,4-diphenyl-1H-imidazole analogs show potent human CB2 agonist activity and high functional selectivity over CB1 receptors, offering potential for chronic pain treatment.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
Cannabinoid CB2 Receptor-Mediated Anti-nociception in Models of Acute and Chronic Pain
Selective CB2 receptor agonists show anti-nociceptive effects in animal models of acute and chronic pain without CNS side effects, offering potential for treatment of inflammatory, post-operative, and neuropathic pain states.
2007·92citations·M. Jhaveri et al.·Molecular Neurobiology
Molecular Neurobiology
Targeting cannabinoid agonists for inflammatory and neuropathic pain
Cannabinoid agonists, particularly selective CB2 agonists and peripherally restricted CB1 or CB1/CB2 dual agonists, show potential for treating inflammatory and neuropathic pain without side effects within the CNS.
2007·100citations·Yuan Cheng et al.·Expert Opinion on Investigational Drugs
Expert Opinion on Investigational Drugs
Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.
GW842166X, a selective CB2 receptor agonist, shows potential as a clinical candidate for treating inflammatory pain with an oral ED50 of 0.1 mg/kg in a rat FCA model.
2007·110citations·G. Giblin et al.·Journal of medicinal chemistry
Journal of medicinal chemistry
CB2 receptor‐mediated antihyperalgesia: possible direct involvement of neural mechanisms
CB2 agonists may reduce chronic pain by acting both at non-neuronal peripheral sites and at neural levels, making them an attractive target for chronic pain treatment.
2006·283citations·M. Beltramo et al.·European Journal of Neuroscience
European Journal of Neuroscience
A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
The CB2-selective agonist GW405833 effectively reduces pain in neuropathic and inflammatory conditions without involving endogenous opioids.
2005·98citations·G. Whiteside et al.·European journal of pharmacology
European journal of pharmacology
Citations
Synthetic cannabinoid receptor agonists: analytical profiles and development of QMPSB, QMMSB, QMPCB, 2F-QMPSB, QMiPSB, and SGT-233.
This study characterized six synthetic cannabinoid receptor agonists (SCRAs) with sulfamoyl benzoate, sulfamoyl benzamide, and N-benzoylpiperidine based structures, providing analytical profiles for forensic and clinical investigations.
2020·6citations·S. Brandt et al.·Drug testing and analysis
Drug testing and analysis
DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL SELECTIVE CANNABINOID RECEPTOR 2 (CB2) LIGANDS WITH THERAPEUTIC POTENTIALS
Novel CB2 ligands with high potency and selectivity show potential therapeutic potential for treating various diseases, including pain, multiple sclerosis, osteoporosis, and cancer.
2015·0citations·Abdulrahman A Almehizia
Comprehensive Review in Current Developments of Imidazole‐Based Medicinal Chemistry
Imidazole-based compounds show broad bioactivities, making them promising candidates for various medicinal uses and diagnostic applications.
2014·576citations·Ling Zhang et al.·Medicinal Research Reviews
Medicinal Research Reviews
Recent development of CB2 selective and peripheral CB1/CB2 cannabinoid receptor ligands.
Selective CB2 receptor ligands have been developed to enhance therapeutic effects without causing central nervous system side-effects, potentially benefiting pain relief, cancer therapy, and nausea control.
2013·22citations·T. Nevalainen·Current medicinal chemistry
Current medicinal chemistry
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Selective CB2 receptor agonists show potential as superior analgesic agents without centrally mediated CB1 effects, making them high value therapeutics for treating pain and other diseases.
2013·131citations·Sangdon Han et al.·Journal of medicinal chemistry
Journal of medicinal chemistry
Synthesis of 1,5-diarylhaloimidazole analogs and their inhibitory activities against PGE₂ production from LPS-treated RAW 264.7 cells.
Halogenated 1,5-diarylimidazole analogs show improved inhibitory activities against COX-2-mediated prostaglandin E2 production in LPS-induced RAW 264.7 cells, with inhibitory activities varying by position and species of substituted halogen.
2012·1citation·Zunhua Yang et al.·Bioorganic & medicinal chemistry
Bioorganic & medicinal chemistry
Highly efficient oxidation of 2-imidazoline-5-carboxylic derivatives to imidazole-5-carboxylic derivatives by dioxygen
Dioxygen-based oxidation efficiently converts 2-imidazoline-5-carboxylic derivatives to imidazole-5-carboxylic derivatives in excellent yields, making it suitable for large-scale 2-imidazole synthesis.
2012·9citations·Yue Huang et al.·Tetrahedron
Tetrahedron
Desulfohaplosamate, a new phosphate-containing steroid from Dasychalina sp., is a selective cannabinoid CB2 receptor ligand
Desulfohaplosamate, a new phosphate-containing steroid from Dasychalina sp., selectively binds to CB2 receptors, making it the first CB receptor ligand belonging to the class of steroids.
2011·24citations·G. Chianese et al.·Steroids
Steroids